Product Code: 138150-01-23
Aptamers Market is Expected to Grow at 15% by 2031. Aptamers are chemically synthesized peptides or oligonucleotide molecules that bind to a specific target nucleic acid, protein, or lipid. Aptamers are used in various fields such as drug delivery, diagnostics, and therapeutics. The global aptamers market expected to witness a lucrative growth during the forecast period owing to the growing investment in research and development, technological advancements, growing usage of aptamers in drug delivery and diagnostics. The ethical issues associated with the use of aptamers and stringent regulatory policies for the product approval hinder the market growth.
The global aptamers market is segmented based on types, applications, and geography. Based on the types, the global aptamers market is segmented into nucleic acid aptamers and peptide aptamers. The nucleic acid aptamers segment is further sub-segmented into DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers. In 2022, the market was dominated by nucleic acid aptamers segment owing to the higher preference, introduction of novel nucleic acid aptamers-based drugs such as Macugen and developing of DNA/RNA based aptamer drug such as NOX-A12, REG1.
Based on applications, in 2022, research and development segmented dominated the global market and expected to retain its dominance during the forecast period. The prime factors for the dominance of segment is the growing use of aptamers in research and development. For instance, Aptagen, LLC is working on the development of aptabodies that overcomes the current restrictions of traditional pharmaceutical drug discovery process.
In 2022, North America led the global aptamers market owing to rapid technological advancements and rising funding & investment to the development of aptamers. Furthermore, the domicile of the key players such as Aptagen, Inc., Regado Biosciences, Inc., and Somalogic, Inc. contributed to the North America market lead. Furthermore, Asia Pacific holds immense market opportunities due to increasing research & development activities and economic growth and expected to grow during the late phase of the forecast period. In Asia Pacific, the market growth is centered in the major economies such as Japan, China, and India due to supportive government initiatives and rising focus on research and development.
The global aptamers market is highly fragmented due to novel technology and new entrants. Key players hold a substantial position in the market due to better market penetration and geographical outreach. However, many startups are focusing on the development of aptamers to soon enter the competition. For instance, in 2017, Base Pair Biotechnologies, Inc., a provider of custom aptamers discovery and development services, received US$ 3.2 million in series A-3 financing round. Thus, entry of new players accounts for the technological advancement thereby contributing to the global aptamers market growth.
Aptamers Market Global Dynamics
Drivers: Rising awareness of the advantages of aptamers over antibodies
Restrains: Low market acceptance as compared to antibodies
Opportunities: Growth in the venture capital funding for research on aptamers
Challenges: Shortage of skilled & trained professionals
Recent Developments
In March 2022, SomaLogic announced the initiation of assaying samples using SomaScan Assay for the European Prospective Investigation into Cancer and Nutrition (EPIC) study by analyzing 210 million protein measurements from 30,000 samples. This will help researchers in predicting cancer by better understanding its nature, which in turn may contribute to market growth by addressing the increased demand.
In August 2021, Aptamer Group, Ltd. and BizCom Japan, Inc. entered into a distribution and marketing agreement to market Optimer discovery and development services in Japan.
In August 2021, Aptamer Group entered a partnership with ProAxsis Limited. As per the partnership, Aptamer Group will develop validated Optimer ligands against critical targets for ProAxsis's diagnostic assays
In July 2021, Aptamer Sciences, Inc. was selected by the Korean government to support a non-clinical project for a new drug development project for COVID-19 treatment and vaccine and will receive a research grant of about USD 0.51 million for one year through this project.
In December 2020 - SomaLogic, Inc. (US) raised USD 81 million from leading life sciences investors Casdin Capital, Farallon Capital Management, and Foresite Capital. This will support the commercialization of the company's products in clinical and life science markets.
In November 2020, SomaLogic, Inc. (US) received funding of USD 121 million to support the expansion and commercialization of its proteomics platform serving the life science and clinical markets.
In June 2018, Aptamer Group (UK) received USD 2.2 million from Meneldor, a biopharmaceutical investment company, and other overseas investors. These funds will be utilized to drive pre-clinical discovery programs involving the development of aptamer drug conjugates (ApDCs).
In November 2017, Base Pair Biotechnologies, Inc. (US) received USD 3.2 million from investors such as Eventi Capital Partners Inc. (Canada) and BioTex, Inc. (US). This funding will be used to acquire new lab instruments and other technologies to help it expand its cellular and molecular analysis capabilities.
Key Players Identified in Aptamers Market include:
Aptagen, LLC, AM Biotechnologies, LLC, Aptamer Solutions Ltd, Aptamer Sciences, Inc., Aptus Biotech S.L., NeoVentures Biotechnology, Base Pair Biotechnologies, Inc., TriLink BioTechnologies, Inc., Regado Biosciences, Inc., Vivonics, Inc., SomaLogic Inc., Noxxon Pharma, Creative Biogene, Auramer, Bio2bind GmbH, IBA GmbH, Barrick Lab, Donovan Biotechnology, LLC And Others.
Historical & Forecast Period
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Aptamers market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Aptamers market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Type
Nucleic Acid Aptamers
DNA-Based Aptamers
RNA-Based Aptamers
XNA-Based Aptamers
Peptide Aptamers
Application
Diagnostics
Therapeutics Development
Research and Development
End User
Academic and Government Research Institutes
Biotechnology and Pharmaceutical Companies
Contract Research
Organizations
Others
Region Segment (2021-2031; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Global Impact of Covid-19 Segment (2020-2021; US$ Million )
Pre Covid-19 situation
Post Covid-19 situation
Key questions answered in this report
What are the key micro and macro environmental factors that are impacting the growth of Aptamers market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2030.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Aptamers market?
Which is the largest regional market for Aptamers market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Aptamers market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Aptamers market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Aptamers Market
- 2.2. Global Aptamers Market, By Type, 2021 (US$ Million)
- 2.3. Global Aptamers Market, By Application, 2021 (US$ Million)
- 2.4. Global Aptamers Market, By End User, 2021 (US$ Million)
- 2.5. Global Aptamers Market, By Geography, 2021 (US$ Million)
- 2.6. Attractive Investment Proposition by Geography, 2021
3. Aptamers Market: Competitive Analysis
- 3.1. Market Positioning of Key Aptamers Market Vendors
- 3.2. Strategies Adopted by Aptamers Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2021 Versus 2030
4. Aptamers Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Aptamers Market Value, 2020 - 2030, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
5. Aptamers Market: By Type, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Nucleic Acid Aptamers
- 5.3.1.1. DNA-Based Aptamers
- 5.3.1.2. RNA-Based Aptamers
- 5.3.1.3. XNA-Based Aptamers
- 5.3.2. Peptide Aptamers
6. Aptamers Market: By Application, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2021 Versus 2030
- 6.3. Market Segmentation
- 6.3.1. Diagnostics
- 6.3.2. Therapeutics Development
- 6.3.3. Research and Development
7. Aptamers Market: By End User, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2021 Versus 2030
- 7.3. Market Segmentation
- 7.3.1. Academic and Government Research Institutes
- 7.3.2. Biotechnology and Pharmaceutical Companies
- 7.3.3. Contract Research
- 7.3.4. Organizations
- 7.3.5. Others
8. North America Aptamers Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Aptamers Market: By Type, 2020-2030, USD (Million)
- 8.3. Aptamers Market: By Application, 2020-2030, USD (Million)
- 8.4. Aptamers Market: By End User, 2020-2030, USD (Million)
- 8.5.Aptamers Market: By Region, 2020-2030, USD (Million)
- 8.5.1.North America
- 8.5.1.1. U.S.
- 8.5.1.1.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 8.5.1.1.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 8.5.1.1.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 8.5.1.2. Canada
- 8.5.1.2.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 8.5.1.2.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 8.5.1.2.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 8.5.1.3. Rest of North America
- 8.5.1.3.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 8.5.1.3.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 8.5.1.3.1. Aptamers Market: By End User, 2020-2030, USD (Million)
9. UK and European Union Aptamers Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Aptamers Market: By Type, 2020-2030, USD (Million)
- 9.3. Aptamers Market: By Application, 2020-2030, USD (Million)
- 9.4. Aptamers Market: By End User, 2020-2030, USD (Million)
- 9.5.Aptamers Market: By Region, 2020-2030, USD (Million)
- 9.5.1.UK and European Union
- 9.5.1.1. UK
- 9.5.1.1.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 9.5.1.1.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 9.5.1.1.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 9.5.1.2. Germany
- 9.5.1.2.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 9.5.1.2.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 9.5.1.2.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 9.5.1.3. Spain
- 9.5.1.3.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 9.5.1.3.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 9.5.1.3.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 9.5.1.4. Italy
- 9.5.1.4.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 9.5.1.4.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 9.5.1.4.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 9.5.1.5. France
- 9.5.1.5.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 9.5.1.5.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 9.5.1.5.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 9.5.1.6. Rest of Europe
- 9.5.1.6.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 9.5.1.6.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 9.5.1.6.1. Aptamers Market: By End User, 2020-2030, USD (Million)
10. Asia Pacific Aptamers Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Aptamers Market: By Type, 2020-2030, USD (Million)
- 10.3. Aptamers Market: By Application, 2020-2030, USD (Million)
- 10.4. Aptamers Market: By End User, 2020-2030, USD (Million)
- 10.5.Aptamers Market: By Region, 2020-2030, USD (Million)
- 10.5.1.Asia Pacific
- 10.5.1.1. China
- 10.5.1.1.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 10.5.1.1.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 10.5.1.1.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 10.5.1.2. Japan
- 10.5.1.2.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 10.5.1.2.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 10.5.1.2.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 10.5.1.3. India
- 10.5.1.3.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 10.5.1.3.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 10.5.1.3.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 10.5.1.4. Australia
- 10.5.1.4.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 10.5.1.4.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 10.5.1.4.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 10.5.1.5. South Korea
- 10.5.1.5.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 10.5.1.5.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 10.5.1.5.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 10.5.1.6. Rest of Asia Pacific
- 10.5.1.6.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 10.5.1.6.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 10.5.1.6.1. Aptamers Market: By End User, 2020-2030, USD (Million)
11. Latin America Aptamers Market, 2020-2030, USD (Million)
- 11.1. Market Overview
- 11.2. Aptamers Market: By Type, 2020-2030, USD (Million)
- 11.3. Aptamers Market: By Application, 2020-2030, USD (Million)
- 11.4. Aptamers Market: By End User, 2020-2030, USD (Million)
- 11.5.Aptamers Market: By Region, 2020-2030, USD (Million)
- 11.5.1.Latin America
- 11.5.1.1. Brazil
- 11.5.1.1.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 11.5.1.1.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 11.5.1.1.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 11.5.1.2. Mexico
- 11.5.1.2.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 11.5.1.2.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 11.5.1.2.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 11.5.1.3. Rest of Latin America
- 11.5.1.3.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 11.5.1.3.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 11.5.1.3.1. Aptamers Market: By End User, 2020-2030, USD (Million)
12. Middle East and Africa Aptamers Market, 2020-2030, USD (Million)
- 12.1. Market Overview
- 12.2. Aptamers Market: By Type, 2020-2030, USD (Million)
- 12.3. Aptamers Market: By Application, 2020-2030, USD (Million)
- 12.4. Aptamers Market: By End User, 2020-2030, USD (Million)
- 12.5.Aptamers Market: By Region, 2020-2030, USD (Million)
- 12.5.1.Middle East and Africa
- 12.5.1.1. GCC
- 12.5.1.1.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 12.5.1.1.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 12.5.1.1.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 12.5.1.2. Africa
- 12.5.1.2.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 12.5.1.2.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 12.5.1.2.1. Aptamers Market: By End User, 2020-2030, USD (Million)
- 12.5.1.3. Rest of Middle East and Africa
- 12.5.1.3.1. Aptamers Market: By Type, 2020-2030, USD (Million)
- 12.5.1.3.1. Aptamers Market: By Application, 2020-2030, USD (Million)
- 12.5.1.3.1. Aptamers Market: By End User, 2020-2030, USD (Million)
13. Company Profile
- 13.1. Aptagen, LLC
- 13.1.1. Company Overview
- 13.1.2. Financial Performance
- 13.1.3. Product Portfolio
- 13.1.4. Strategic Initiatives
- 13.2. AM Biotechnologies, LLC
- 13.2.1. Company Overview
- 13.2.2. Financial Performance
- 13.2.3. Product Portfolio
- 13.2.4. Strategic Initiatives
- 13.3. Aptamer Solutions Ltd
- 13.3.1. Company Overview
- 13.3.2. Financial Performance
- 13.3.3. Product Portfolio
- 13.3.4. Strategic Initiatives
- 13.4. Aptamer Sciences, Inc.
- 13.4.1. Company Overview
- 13.4.2. Financial Performance
- 13.4.3. Product Portfolio
- 13.4.4. Strategic Initiatives
- 13.5. Aptus Biotech S.L.
- 13.5.1. Company Overview
- 13.5.2. Financial Performance
- 13.5.3. Product Portfolio
- 13.5.4. Strategic Initiatives
- 13.6. NeoVentures Biotechnology
- 13.6.1. Company Overview
- 13.6.2. Financial Performance
- 13.6.3. Product Portfolio
- 13.6.4. Strategic Initiatives
- 13.7. Base Pair Biotechnologies, Inc.
- 13.7.1. Company Overview
- 13.7.2. Financial Performance
- 13.7.3. Product Portfolio
- 13.7.4. Strategic Initiatives
- 13.8. TriLink BioTechnologies, Inc.
- 13.8.1. Company Overview
- 13.8.2. Financial Performance
- 13.8.3. Product Portfolio
- 13.8.4. Strategic Initiatives
- 13.9. Regado Biosciences, Inc.
- 13.9.1. Company Overview
- 13.9.2. Financial Performance
- 13.9.3. Product Portfolio
- 13.9.4. Strategic Initiatives
- 13.10. Vivonics, Inc.
- 13.10.1. Company Overview
- 13.10.2. Financial Performance
- 13.10.3. Product Portfolio
- 13.10.4. Strategic Initiatives
- 13.11. SomaLogic Inc.
- 13.11.1. Company Overview
- 13.11.2. Financial Performance
- 13.11.3. Product Portfolio
- 13.11.4. Strategic Initiatives
- 13.12. Noxxon Pharma
- 13.12.1. Company Overview
- 13.12.2. Financial Performance
- 13.12.3. Product Portfolio
- 13.12.4. Strategic Initiatives
- 13.13. Creative Biogene
- 13.13.1. Company Overview
- 13.13.2. Financial Performance
- 13.13.3. Product Portfolio
- 13.13.4. Strategic Initiatives
- 13.14. Auramer
- 13.14.1. Company Overview
- 13.14.2. Financial Performance
- 13.14.3. Product Portfolio
- 13.14.4. Strategic Initiatives
- 13.15. Bio2bind GmbH
- 13.15.1. Company Overview
- 13.15.2. Financial Performance
- 13.15.3. Product Portfolio
- 13.15.4. Strategic Initiatives
- 13.16. IBA GmbH
- 13.16.1. Company Overview
- 13.16.2. Financial Performance
- 13.16.3. Product Portfolio
- 13.16.4. Strategic Initiatives
- 13.17. Barrick Lab
- 13.17.1. Company Overview
- 13.17.2. Financial Performance
- 13.17.3. Product Portfolio
- 13.17.4. Strategic Initiatives
- 13.18. Donovan Biotechnology, LLC
- 13.18.1. Company Overview
- 13.18.2. Financial Performance
- 13.18.3. Product Portfolio
- 13.18.4. Strategic Initiatives
- 13.19. Others
- 13.19.1. Company Overview
- 13.19.2. Financial Performance
- 13.19.3. Product Portfolio
- 13.19.4. Strategic Initiatives